NCT06880406 · RECRUITING

Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias

This study is testing whether mitochondria (the energy-producing parts of cells) behave differently in people with Alzheimer's versus other forms of dementia, using a simple cognitive test and a blood draw. Researchers also want to find metabolic markers in blood that may signal those mitochondrial changes. This is a Phase NA observational study — it is collecting data, not testing a treatment.

Eligibility criteria

Inclusion Criteria:
* Neurocognitive disorder with spontaneous complaint or reported for at least 6 months
* Diagnostic process according to current Haute Autorité de Santé (HAS) recommendations.
* cerebrospinal fluid biomarker dosage done within the study center and agreement to bio-collection of residual cerebrospinal fluid
* Patient having agreed to sign the informed consent
* Patient affiliated or beneficiary of a social security scheme
For alzheimer group : diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria (presence of a pathogenic amyloid process in the cerebrospinal fluid)
For non alzheimer group : diagnosis of mild or major neurocognitive disorder according to Manuel diagnostique et statistique des troubles mentaux edition 5 (DSM-V) criteria, not linked to Alzheimer's disease (absence of pathogenic amyloid process in the cerebrospinal fluid)
Exclusion Criteria:
- Vulnerable people

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-07-03

View full record on ClinicalTrials.gov

All APOE4 clinical trials